Company news
Newron Pharmaceuticals S.p.A. news in 2026
Newron Pharmaceuticals S.p.A.'s news releases, calls and decks from 2026, newest first.
Newron Completes Enrollment of Pivotal Phase 3 ENIGMA-TRS 1 Study
October 22, 2026
Newron presents H1 2026 results and provides corporate update
September 22, 2026
Newron Pharmaceuticals S p A presents H1 2026 results and provides corporate update
September 22, 2026
Newron Reports Subscription for EUR 5.5 Million of Shares by Investor Group as Part of Up to EUR 38 Million Total Financing to Advance Phase 3 Evenamide Program
September 8, 2026
Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
September 2, 2026
Newron Provides Update Following Type A Meeting With the FDA
July 2, 2026
Newron Pharmaceuticals to Participate in June Investor Conferences
May 28, 2026
Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study
April 29, 2026
Newron Announces AGM 2026 Results
April 23, 2026
Newron Presents 2025 Financial Results and Provides 2026 Outlook
March 24, 2026
Newron presents 2025 financial results and provides 2026 outlook
March 24, 2026
Newron Pharmaceuticals S p A presents 2025 financial results and provides 2026 outlook
March 24, 2026
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
March 20, 2026
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract
March 19, 2026
Newron Pharmaceuticals S p A announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract
March 19, 2026
Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting
March 18, 2026
Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
March 18, 2026
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
February 16, 2026
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
February 3, 2026
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
January 7, 2026
Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
January 6, 2026
Calls in 2026
Decks in 2026
- FY 2025 Earnings Presentation
Earnings · 38 slides · Mar 24, 2026